HOME >> BIOLOGY >> NEWS
Regenerative medicine to be focus of new institute at University of Pittsburgh School of Medicine and UPMC Health System

eering Initiative, a post he will continue in for at least another year.

Bartley P. Griffith, M.D., the Henry T. Bahnson professor of surgery, who had directed the McGowan Center for Artificial Organ Development since its inception in 1992, will play a major role at the new institute as medical director, continuing to provide vision and leadership of research that has helped the center to achieve world renown.

"This institute will be the most ambitious tissue engineering program in the nation, coupling biology and engineering in all facets of its work," stated Dr. Russell, whose primary academic appointment will now be in the school of medicine's department of surgery. "The University of Pittsburgh and UPMC Health System provide the perfect home for such an enterprise because of its leading programs in organ transplantation, biomedical research and bioengineering."

"One of the attractive features of the McGowan Institute for Regenerative Medicine is that it will enable cutting-edge basic and clinical research to be performed across disciplines, allowing organ and tissue engineering and cellular and regenerative therapies to be developed and swiftly evaluated in the clinical setting," added Arthur S. Levine, M.D., senior vice chancellor, Health Sciences, and dean of the University of Pittsburgh School of Medicine.

"We believe this institute is poised for national prominence. The Pittsburgh region, and more importantly, patients stand to benefit from the exciting developments we can expect to take place in the years to come," said Jeffrey A. Romoff, president of UPMC Health System.

The MIRM is expected to establish itself as a model for technology transfer. In addition, the institute plans to compete for major funding and to establish itself as a location for a National Tissue Engineering Center.

"The establishment of this institute is a natural extension of the McGowan Center's vision and missions, to ease the suffering
'"/>

Contact: Lisa Rossi
rossiL@msx.upmc.edu
412-647-3555
University of Pittsburgh Medical Center
5-Jul-2001


Page: 1 2 3 4

Related biology news :

1. Regenerative chemical turns muscle cells into stem cells
2. Probing the surface of white blood cells to enhance immune system medicine
3. From science fiction to reality: Nanomedicine brings fresh hope to the medical world
4. Annals of internal medicine tip sheet, July 20, 2004
5. Germans must research the history of reproductive medicine during the Nazi era
6. New public policy & aging report highlights facts and fiction about anti-aging medicine
7. K-State business researchers to help with major study on food supply veterinary medicine
8. White House lauds Physiological Society for mentoring underrepresented minorities in biomedicine
9. University of Michigan symposium charts course for the future of telemedicine
10. Researchers show chronic sinusitis is immune disorder; antifungal medicine effective treatment
11. Making of mouse marks move toward mitochondrial medicine

Post Your Comments:
(Date:10/30/2014)... therapeutics present unique challenges when it comes to ... harm. New consensus guidelines for toxicity testing that ... characteristics of these novel biopharmaceuticals are presented in ... from Mary Ann Liebert, Inc. publishers . ... Nucleic Acid Therapeutics website until November 30, ...
(Date:10/30/2014)... Oct. 29, 2014  Securus Technologies, a ... technology solutions for public safety, investigation, corrections ... deployed exciting enhancements to its THREADS™ product, ... provide actionable intelligence and focused leads for ... drive technological innovation through identifying and delivering ...
(Date:10/29/2014)... Beaverton, OR) New research presented at the ... in Houston, TX showed for the first time ... in women using a readily available nutritional supplement, ... by Dr. Judith A. Smith, Pharm.D., associate professor ... Sciences at The University of Texas Health Science ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
(Date:10/30/2014)... , Oct. 30, 2014  Regado Biosciences, Inc. ... will hold a conference call and live audio webcast ... to discuss its third quarter 2014 financial results. ... call by dialing (888) 347-1165 for domestic callers or ... be webcast live under the investor relations section of ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
(Date:10/27/2014)... October 27, 2014 The new ... Type (High & Medium), Sub-type (Primary & Secondary), ... Infrastructure & Transportation & Power Generation) - Trends ... GIS market with analysis and forecasting of the ... Data Tables with 52 Figures spread through 146 ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
Breaking Biology Technology:Regado Biosciences to Provide Third Quarter 2014 Financial Results 2CU Denver study says upgrading infrastructure could reduce flood damage 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
Cached News: